Christian M Matter

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6283156/publications.pdf

Version: 2024-02-01

106 papers 4,612 citations

35 h-index 106344 65 g-index

106 all docs

106 docs citations

106 times ranked 8005 citing authors

#	Article	IF	Citations
1	Methylation of the Hippo effector YAP by the methyltransferase SETD7 drives myocardial ischaemic injury: a translational study. Cardiovascular Research, 2023, 118, 3374-3385.	3.8	10
2	Smoking Cessation in People With and Without Diabetes After Acute Coronary Syndrome. Nicotine and Tobacco Research, 2023, 25, 58-65.	2.6	2
3	Is the amount of glow predicting the fire? Residual inflammatory risk after percutaneous coronary intervention. European Heart Journal, 2022, 43, e10-e13.	2.2	5
4	Vascular endothelial tissue factor contributes to trimethylamine N-oxide-enhanced arterial thrombosis. Cardiovascular Research, 2022, 118, 2367-2384.	3.8	45
5	Controlled-Level EVERolimus in Acute Coronary Syndrome (CLEVER-ACS) - A phase II, randomized, double-blind, multi-center, placebo-controlled trial. American Heart Journal, 2022, 247, 33-41.	2.7	8
6	The BET Protein Inhibitor Apabetalone Rescues Diabetes-Induced Impairment of Angiogenic Response by Epigenetic Regulation of Thrombospondin-1. Antioxidants and Redox Signaling, 2022, 36, 667-684.	5.4	15
7	Deletion of fibroblast activation protein provides atheroprotection. Cardiovascular Research, 2021, 117, 1060-1069.	3.8	20
8	Comparison of P2Y12 receptor inhibitors in patients with ST-elevation myocardial infarction in clinical practice: a propensity score analysis of five contemporary European registries. European Heart Journal - Cardiovascular Pharmacotherapy, 2021, 7, 94-103.	3.0	13
9	Prognostic value of total testosterone levels in patients with acute coronary syndromes. European Journal of Preventive Cardiology, 2021, 28, 235-242.	1.8	7
10	Eligibility for PCSK9 inhibitors based on the 2019 ESC/EAS and 2018 ACC/AHA guidelines. European Journal of Preventive Cardiology, 2021, 28, 59-65.	1.8	30
11	Prognostic value of inflammatory biomarkers and GRACE score for cardiac death and acute kidney injury after acute coronary syndromes. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 445-452.	1.0	5
12	Novel Blood Biomarkers for a Diagnostic Workup of Acute Aortic Dissection. Diagnostics, 2021, 11, 615.	2.6	14
13	Residual inflammatory risk at 12 months after acute coronary syndromes is frequent and associated with combined adverse events. Atherosclerosis, 2021, 320, 31-37.	0.8	7
14	Improving 1-year mortality prediction in ACS patients using machine learning. European Heart Journal: Acute Cardiovascular Care, 2021, 10, 855-865.	1.0	9
15	Effects of the PCSK9 antibody alirocumab on coronary atherosclerosis in patients with acute myocardial infarction: a serial, multivessel, intravascular ultrasound, near-infrared spectroscopy and optical coherence tomography imaging study–Rationale and design of the PACMAN-AMI trial. American Heart Journal, 2021, 238, 33-44.	2.7	17
16	CCN family member 1 (CCN1) is an early marker of infarct size and left ventricular dysfunction in STEMI patients. Atherosclerosis, 2021, 335, 77-83.	0.8	6
17	Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside. Frontiers in Physiology, 2021, 12, 755060.	2.8	13
18	Association between self-reported motivation to quit smoking with effectiveness of smoking cessation intervention among patients hospitalized for acute coronary syndromes in Switzerland. Preventive Medicine Reports, 2021, 24, 101583.	1.8	0

#	Article	IF	CITATIONS
19	Thrombin Generation to Predict the Risk of Venous Thromboembolism Recurrence, Major Bleeding and Death in the Elderly: A Prospective Multicenter Cohort Study. Blood, 2021, 138, 3222-3222.	1.4	1
20	Prognostic values of fasting hyperglycaemia in non-diabetic patients with acute coronary syndrome: A prospective cohort study. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 589-598.	1.0	7
21	Endothelial SIRT6 blunts stroke size and neurological deficit by preserving blood–brain barrier integrity: a translational study. European Heart Journal, 2020, 41, 1575-1587.	2.2	54
22	Cardiomyocyte-Specific JunD Overexpression Increases Infarct Size following Ischemia/Reperfusion Cardiac Injury by Downregulating Sirt3. Thrombosis and Haemostasis, 2020, 120, 168-180.	3 . 4	13
23	Control of cardiovascular risk factors and health behaviors in patients post acute coronary syndromes eligible for protein convertase subtilisin/kexin-9 inhibitors. International Journal of Cardiology, 2020, 299, 289-295.	1.7	1
24	Intensified lipid lowering using ezetimibe after publication of the IMPROVE-IT trial: A contemporary analysis from the SPUM-ACS cohort. International Journal of Cardiology, 2020, 303, 8-13.	1.7	5
25	Prognosis of Patients with Chronic and Hospital-Acquired Anaemia After Acute Coronary Syndromes. Journal of Cardiovascular Translational Research, 2020, 13, 618-628.	2.4	8
26	Role of the Nuclear Receptor Corepressor 1 (NCOR1) in Atherosclerosis and Associated Immunometabolic Diseases. Frontiers in Immunology, 2020, 11, 569358.	4.8	9
27	Prognostic role of plasma galectin-3 levels in acute coronary syndrome. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 869-878.	1.0	5
28	Optimal Timing of Invasive Coronary Angiography following NSTEMI. Journal of Interventional Cardiology, 2020, 2020, 1-9.	1.2	6
29	Clinical predictors of left ventricular involvement in arrhythmogenic right ventricular cardiomyopathy. American Heart Journal, 2020, 223, 34-43.	2.7	13
30	Elevated HbA1c is not associated with recurrent venous thromboembolism in the elderly, but with all-cause mortality– the SWEETCO 65+ study. Scientific Reports, 2020, 10, 2495.	3.3	6
31	Sirt6 deletion in bone marrow-derived cells increases atherosclerosis $\hat{a} \in \text{``Central role of macrophage}$ scavenger receptor 1. Journal of Molecular and Cellular Cardiology, 2020, 139, 24-32.	1.9	26
32	Deleterious role of endothelial lectin-like oxidized low-density lipoprotein receptor-1 in ischaemia/reperfusion cerebral injury. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 2233-2245.	4.3	15
33	Non-Linear Relationship between Anti-Apolipoprotein A-1 IgGs and Cardiovascular Outcomes in Patients with Acute Coronary Syndromes. Journal of Clinical Medicine, 2019, 8, 1002.	2.4	11
34	Risk stratification of elderly patients with acute pulmonary embolism. European Journal of Clinical Investigation, 2019, 49, e13154.	3.4	3
35	Diabetes and baseline glucose are associated with inflammation, left ventricular function and short- and long-term outcome in acute coronary syndromes: role of the novel biomarker Cyr 61. Cardiovascular Diabetology, 2019, 18, 142.	6.8	21
36	Evolocumab for Early Reduction of LDLÂCholesterol Levels in Patients With Acute Coronary Syndromes (EVOPACS). Journal of the American College of Cardiology, 2019, 74, 2452-2462.	2.8	135

#	Article	IF	CITATIONS
37	Trimethyllysine, a trimethylamine N-oxide precursor, provides near- and long-term prognostic value in patients presenting with acute coronary syndromes. European Heart Journal, 2019, 40, 2700-2709.	2.2	79
38	Clinical impact of a structured secondary cardiovascular prevention program following acute coronary syndromes: A prospective multicenter healthcare intervention. PLoS ONE, 2019, 14, e0211464.	2.5	6
39	Inflammation during acute coronary syndromes â€" Risk of cardiovascular events and bleeding. International Journal of Cardiology, 2019, 287, 13-18.	1.7	22
40	Prognostic value of elevated lipoprotein(a) in patients with acute coronary syndromes. European Journal of Clinical Investigation, 2019, 49, e13117.	3.4	24
41	Interleukin- $1\hat{l}^2$ Mediates Arterial Thrombus Formation via NET-Associated Tissue Factor. Journal of Clinical Medicine, 2019, 8, 2072.	2.4	70
42	A high Gas6 level in plasma predicts venous thromboembolism recurrence, major bleeding and mortality in the elderly: a prospective multicenter cohort study. Journal of Thrombosis and Haemostasis, 2019, 17, 306-318.	3.8	9
43	Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European Society of Cardiology. Cardiovascular Research, 2019, 115 , 10 - 19 .	3.8	72
44	Obesity-induced activation of JunD promotes myocardial lipid accumulation and metabolic cardiomyopathy. European Heart Journal, 2019, 40, 997-1008.	2.2	69
45	Gut microbiota-dependent trimethylamine-N-oxide (TMAO) shows a U-shaped association with mortality but not with recurrent venous thromboembolism. Thrombosis Research, 2019, 174, 40-47.	1.7	29
46	Gender and age differences in outcomes of patients with acute coronary syndromes referred for coronary angiography. Catheterization and Cardiovascular Interventions, 2019, 93, 16-24.	1.7	3
47	Association between income and control of cardiovascular risk factors after acute coronary syndromes: an observational study. Swiss Medical Weekly, 2019, 149, w20049.	1.6	1
48	Incidence, Predictors, and Clinical Impact of Early Prasugrel Cessation in Patients With STâ€Elevation Myocardial Infarction. Journal of the American Heart Association, 2018, 7, .	3.7	11
49	Loss of Sirt3 accelerates arterial thrombosis by increasing formation of neutrophil extracellular traps and plasma tissue factor activity. Cardiovascular Research, 2018, 114, 1178-1188.	3.8	44
50	Predictors and Outcomes of Recurrent Venous Thromboembolism in Elderly Patients. American Journal of Medicine, 2018, 131, 703.e7-703.e16.	1.5	17
51	Improved risk stratification of patients with acute coronary syndromes using a combination of hsTnT, NT-proBNP and hsCRP with the GRACE score. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 129-138.	1.0	70
52	Thrombus aspiration in acute coronary syndromes: prevalence, procedural success, change in serial troponin T levels and clinical outcomes in a contemporary Swiss cohort. European Heart Journal: Acute Cardiovascular Care, 2018, 7, 522-531.	1.0	7
53	Design of the randomized, placeboâ€controlled evolocumab for early reduction of LDLâ€cholesterol levels in patients with acute coronary syndromes (EVOPACS) trial. Clinical Cardiology, 2018, 41, 1513-1520.	1.8	20
54	Prognostic Value of SYNTAX Score II in Patients with Acute Coronary Syndromes Referred for Invasive Management: A Subanalysis from the SPUM and COMFORTABLE AMI Cohorts. Cardiology Research and Practice, 2018, 2018, 1-11.	1.1	9

#	Article	IF	Citations
55	The effect of oxygen in Sirt3-mediated myocardial protection: a proof-of-concept study in cultured cardiomyoblasts. Journal of Thrombosis and Thrombolysis, 2018, 46, 102-112.	2.1	O
56	Interplay between hypercholesterolaemia and inflammation in atherosclerosis: Translating experimental targets into clinical practice. European Journal of Preventive Cardiology, 2018, 25, 948-955.	1.8	46
57	Prognosis of cardiovascular and non-cardiovascular multimorbidity after acute coronary syndrome. PLoS ONE, 2018, 13, e0195174.	2.5	21
58	Future directions for therapeutic strategies in post-ischaemic vascularization: a position paper from European Society of Cardiology Working Group on Atherosclerosis and Vascular Biology. Cardiovascular Research, 2018, 114, 1411-1421.	3.8	19
59	Prognostic value of pulse pressure after an acute coronary syndrome. Atherosclerosis, 2018, 277, 219-226.	0.8	15
60	Predictive value of the age, creatinine, and ejection fraction (ACEF) score in patients with acute coronary syndromes. International Journal of Cardiology, 2018, 270, 7-13.	1.7	33
61	Brain-derived neurotrophic factor Val66Met polymorphism in depression and thrombosis: SIRT1 as a possible mediator. European Heart Journal, 2017, 38, ehv692.	2.2	10
62	Profiling and validation of circulating microRNAs for cardiovascular events in patients presenting with ST-segment elevation myocardial infarction. European Heart Journal, 2017, 38, ehw563.	2.2	77
63	Increased Proangiogenic Activity of Mobilized CD34 ⁺ Progenitor Cells of Patients With Acute ST-Segment–Elevation Myocardial Infarction. Arteriosclerosis, Thrombosis, and Vascular Biology, 2017, 37, 341-349.	2.4	40
64	Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. European Heart Journal, 2017, 38, ehw582.	2.2	317
65	Diabetic patients with acute coronary syndromes in contemporary European registries: characteristics and outcomes. European Heart Journal - Cardiovascular Pharmacotherapy, 2017, 3, 198-213.	3.0	18
66	Inhibition of Vascular câ€Jun Nâ€Terminal Kinase 2 Improves Obesityâ€Induced Endothelial Dysfunction After Rouxâ€enâ€Y Gastric Bypass. Journal of the American Heart Association, 2017, 6, .	3.7	4
67	Eligibility for PCSK9 Inhibitors According to American College of Cardiology (ACC) and European Society of Cardiology/European Atherosclerosis Society (ESC/EAS) Guidelines After Acute Coronary Syndromes. Journal of the American Heart Association, 2017, 6, .	3.7	29
68	Predictors and Causes of Long-Term Mortality in Elderly Patients with Acute Venous Thromboembolism: A Prospective Cohort Study. American Journal of Medicine, 2017, 130, 198-206.	1.5	78
69	Cysteine-rich angiogenic inducer 61 (Cyr61): a novel soluble biomarker of acute myocardial injury improves risk stratification after acute coronary syndromes. European Heart Journal, 2017, 38, 3493-3502.	2.2	46
70	Protective role of the co-stimulator CD27 receptor and regulatory T cells in early atherogenesis. European Heart Journal, 2017, 38, 3600-3602.	2.2	2
71	Mild endothelial dysfunction in Sirt3 knockout mice fed a high-cholesterol diet: protective role of a novel C/EBP-Î ² -dependent feedback regulation of SOD2. Basic Research in Cardiology, 2016, 111, 33.	5. 9	28
72	Plasma ceramides predict cardiovascular death in patients with stable coronary artery disease and acute coronary syndromes beyond LDL-cholesterol. European Heart Journal, 2016, 37, 1967-1976.	2.2	433

#	Article	IF	CITATIONS
73	Prognosis of Patients With Familial Hypercholesterolemia After Acute Coronary Syndromes. Circulation, 2016, 134, 698-709.	1.6	99
74	Echocardiography does not predict mortality in hemodynamically stable elderly patients with acute pulmonary embolism. Thrombosis Research, 2016, 145, 67-71.	1.7	11
75	Pre-hospital alarm activation for STEMI patients undergoing primary percutaneous coronary intervention in the era of transradial procedures. European Journal of Internal Medicine, 2016, 35, 83-88.	2.2	1
76	Uptake and efficacy of a systematic intensive smoking cessation intervention using motivational interviewing for smokers hospitalised for an acute coronary syndrome: a multicentre before–after study with parallel group comparisons. BMJ Open, 2016, 6, e011520.	1.9	18
77	Decreased phosphatidylcholine plasmalogens $\hat{a}\in$ A putative novel lipid signature in patients with stable coronary artery disease and acute myocardial infarction. Atherosclerosis, 2016, 246, 130-140.	0.8	47
78	Prognostic value of PCSK9 levels in patients with acute coronary syndromes. European Heart Journal, 2016, 37, 546-553.	2.2	120
79	Changes of coronary plaque composition correlate with C-reactive protein levels in patients with ST-elevation myocardial infarction following high-intensity statin therapy. Atherosclerosis, 2016, 247, 154-160.	0.8	22
80	Use, patient selection and outcomes of P2Y12 receptor inhibitor treatment in patients with STEMI based on contemporary European registries. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 152-167.	3.0	50
81	P2Y12 receptor inhibitors in patients with non-ST-elevation acute coronary syndrome in the real world: use, patient selection, and outcomes from contemporary European registries. European Heart Journal - Cardiovascular Pharmacotherapy, 2016, 2, 229-243.	3.0	46
82	Anticoagulation Management Practices and Outcomes in Elderly Patients with Acute Venous Thromboembolism: A Clinical Research Study. PLoS ONE, 2016, 11, e0148348.	2.5	10
83	Hospital revascularisation capability and quality of care after an acute coronary syndrome in Switzerland. Swiss Medical Weekly, 2016, 146, w14275.	1.6	2
84	The Sirt1 activator SRT3025 provides atheroprotection in Apoeâ [°] /â [°] mice by reducing hepatic Pcsk9 secretion and enhancing Ldlr expression. European Heart Journal, 2015, 36, 51-59.	2.2	117
85	Low statin use in adults hospitalized with acute coronary syndrome. Preventive Medicine, 2015, 77, 131-136.	3.4	18
86	Contemporary registries on P2Y12 inhibitors in patients with acute coronary syndromes in Europe: overview and methodological considerations: Table 1. European Heart Journal - Cardiovascular Pharmacotherapy, 2015, 1, 232-244.	3.0	13
87	Reasons for discontinuation of recommended therapies according to the patients after acute coronary syndromes. European Journal of Internal Medicine, 2015, 26, 56-62.	2.2	37
88	Rapid and Body Weight–Independent Improvement of Endothelial and High-Density Lipoprotein Function After Roux-en-Y Gastric Bypass. Circulation, 2015, 131, 871-881.	1.6	103
89	Expected impact of applying new 2013 AHA/ACC cholesterol guidelines criteria on the recommended lipid target achievement after acute coronary syndromes. Atherosclerosis, 2015, 239, 118-124.	0.8	26
90	Circulating FABP4 Is a Prognostic Biomarker in Patients With Acute Coronary Syndrome but Not in Asymptomatic Individuals. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1872-1879.	2.4	36

#	Article	IF	CITATIONS
91	Prevalence and management of familial hypercholesterolaemia in patients with acute coronary syndromes. European Heart Journal, 2015, 36, 2438-2445.	2.2	129
92	Protective effects of sirtuins in cardiovascular diseases: from bench to bedside. European Heart Journal, 2015, 36, 3404-3412.	2.2	354
93	Safety profile of prasugrel and clopidogrel in patients with acute coronary syndromes in Switzerland. Heart, 2015, 101, 854-863.	2.9	38
94	Clonal restriction and predominance of regulatory T cells in coronary thrombi of patients with acute coronary syndromes. European Heart Journal, 2015, 36, 1041-1048.	2.2	48
95	Effect of high-intensity statin therapy on atherosclerosis in non-infarct-related coronary arteries (IBIS-4): a serial intravascular ultrasonography study. European Heart Journal, 2015, 36, 490-500.	2.2	168
96	Quality of Care after Acute Coronary Syndromes in a Prospective Cohort with Reasons for Non-Prescription of Recommended Medications. PLoS ONE, 2014, 9, e93147.	2.5	28
97	The Adherence to Initial Processes of Care in Elderly Patients with Acute Venous Thromboembolism. PLoS ONE, 2014, 9, e100164.	2.5	3
98	Endothelial overexpression of LOX-1 increases plaque formation and promotes atherosclerosis in vivo. European Heart Journal, 2014, 35, 2839-2848.	2.2	82
99	Effect of Biolimus-Eluting Stents With Biodegradable Polymer vs Bare-Metal Stents on Cardiovascular Events Among Patients With Acute Myocardial Infarction. JAMA - Journal of the American Medical Association, 2012, 308, 777.	7.4	278
100	High-sensitivity Troponinsâ€"Difficult Friends in Acute Coronary Syndromes. US Cardiology Review, 2012, 9, 121-125.	0.5	0
101	Imaging of the unstable plaque: how far have we got?. European Heart Journal, 2009, 30, 2566-2574.	2.2	84
102	Effects of Tacrolimus or Sirolimus on Proliferation of Vascular Smooth Muscle and Endothelial Cells. Journal of Cardiovascular Pharmacology, 2006, 48, 286-292.	1.9	100
103	Increased Balloon-Induced Inflammation, Proliferation, and Neointima Formation in Apolipoprotein E () Tj ETQq1 1	0.784314 2.0	1 ggBT /Ove
104	Role of Endogenous Fas (CD95/Apo-1) Ligand in Balloon-Induced Apoptosis, Inflammation, and Neointima Formation. Circulation, 2006, 113, 1879-1887.	1.6	35
105	18 F-Choline Images Murine Atherosclerotic Plaques Ex Vivo. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 584-589.	2.4	111
106	Coronary stent thrombosis in acute coronary syndromes. Cardiovascular Medicine(Switzerland), 0, , .	0.0	0